While SGLT2 inhibitors are known to reduce HF events among patients with CKD, HF or T2D and high CV risk30–36, EMPACT-MI was the first study to show the benefit in risk reduction for HF in patients with acute MI2. Here, SLC5A2 is linked to chronic kidney disease.